PT2621539T - Nanopartículas de auto-montagem para a libertação de biofosfonatos no tratamento de cancros humanos - Google Patents

Nanopartículas de auto-montagem para a libertação de biofosfonatos no tratamento de cancros humanos

Info

Publication number
PT2621539T
PT2621539T PT117763821T PT11776382T PT2621539T PT 2621539 T PT2621539 T PT 2621539T PT 117763821 T PT117763821 T PT 117763821T PT 11776382 T PT11776382 T PT 11776382T PT 2621539 T PT2621539 T PT 2621539T
Authority
PT
Portugal
Prior art keywords
bisphosphonates
self
release
treatment
human cancers
Prior art date
Application number
PT117763821T
Other languages
English (en)
Inventor
Salzano Giuseppina
Marra Monica
Leonetti Carlo
Original Assignee
St Fisioterapici Ospitalieri
Giuseppe De Rosa
Michele Caraglia
Pierfrancesco Tassone
Alberto Abbruzzese Saccardi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Fisioterapici Ospitalieri, Giuseppe De Rosa, Michele Caraglia, Pierfrancesco Tassone, Alberto Abbruzzese Saccardi filed Critical St Fisioterapici Ospitalieri
Publication of PT2621539T publication Critical patent/PT2621539T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
PT117763821T 2010-10-01 2011-09-30 Nanopartículas de auto-montagem para a libertação de biofosfonatos no tratamento de cancros humanos PT2621539T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITFI2010A000206A IT1401882B1 (it) 2010-10-01 2010-10-01 Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.

Publications (1)

Publication Number Publication Date
PT2621539T true PT2621539T (pt) 2018-07-27

Family

ID=43447393

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117763821T PT2621539T (pt) 2010-10-01 2011-09-30 Nanopartículas de auto-montagem para a libertação de biofosfonatos no tratamento de cancros humanos

Country Status (7)

Country Link
US (1) US9226897B2 (pt)
EP (1) EP2621539B1 (pt)
DK (1) DK2621539T3 (pt)
ES (1) ES2678498T3 (pt)
IT (1) IT1401882B1 (pt)
PT (1) PT2621539T (pt)
WO (1) WO2012042024A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
RU2519120C1 (ru) * 2012-11-06 2014-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
GB201319363D0 (en) 2013-11-01 2013-12-18 Uni I Oslo Compounds
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
KR101577271B1 (ko) 2014-03-24 2015-12-15 가톨릭대학교 산학협력단 칼슘 이온 및 친수성 비스포스포네이트를 이용한 나노복합체의 제조방법 및 상기 나노복합체를 이용한 약물전달체
US20180318216A1 (en) * 2015-11-20 2018-11-08 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CN106006593B (zh) * 2016-05-18 2018-08-17 西南交通大学 一种简便高效的纳米磷酸钙制备方法
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ANY COMBINATION THEREOF
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
CN112316153B (zh) * 2020-11-24 2023-08-25 中山大学附属第七医院(深圳) 一种抗肿瘤的药物组合物及其应用
CN112675130B (zh) * 2020-12-29 2023-04-25 中国人民解放军总医院第三医学中心 空心纳米颗粒在制备骨质疏松治疗药物中的应用
CN112724175A (zh) * 2020-12-30 2021-04-30 华南理工大学 一种米诺膦酸钙配合物及其制备方法
AU2022302784A1 (en) 2021-06-28 2023-12-21 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
PL441261A1 (pl) * 2022-05-24 2023-11-27 Politechnika Warszawska Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10016559A1 (de) * 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
FR2848850B1 (fr) * 2002-12-20 2005-06-24 Guerbet Sa Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
US20100098632A1 (en) * 2006-07-12 2010-04-22 Russell Stephen J Hydroxyapatite particles
US8821943B2 (en) * 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20090215729A1 (en) * 2008-02-19 2009-08-27 Johnson Erin M Microparticle compositions to modify cancer promoting cells
CA2720418A1 (en) * 2008-04-04 2009-10-08 Novartis Ag Pharmaceutical composition with bisphosphonate
US20130184835A1 (en) * 2010-07-09 2013-07-18 Board Of Regents Of The Unversity Of Texas System Biodegradable scaffolds

Also Published As

Publication number Publication date
DK2621539T3 (en) 2018-07-30
EP2621539A1 (en) 2013-08-07
WO2012042024A1 (en) 2012-04-05
US9226897B2 (en) 2016-01-05
ES2678498T8 (es) 2018-09-28
ITFI20100206A1 (it) 2012-04-02
ES2678498T3 (es) 2018-08-13
US20140086979A1 (en) 2014-03-27
IT1401882B1 (it) 2013-08-28
EP2621539B1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
PT2621539T (pt) Nanopartículas de auto-montagem para a libertação de biofosfonatos no tratamento de cancros humanos
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2729180A4 (en) METAL-BISPHOSPHONATE NANOPARTICLES FOR ANTICANCER THERAPY AND IMAGING, AND FOR TREATING BONE DISORDERS
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2623401A4 (en) FRONT PARTS STRUCTURE FOR A VEHICLE BODY
EP2588140A4 (en) DENTAL COMPOUNDS WITH NANOPARTICLES OF AMORPHIC CALCIUM PHOSPHATE
SG10201508495VA (en) Combination treatment of cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
EP2591363A4 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER
ZA201300218B (en) Treatment of blood cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EP2656837A4 (en) LIPID NANOPARTICLES FOR THE TREATMENT OF OCULAR DISEASES
ZA201209452B (en) Gold complexes for use in the treatment of cancer
PL2556834T3 (pl) Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego serca
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
HUE055818T2 (hu) Eszköz bõrsérülés kezelésére
PL2566579T3 (pl) Urządzenie medyczne do magnetoterapii
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201001659D0 (en) Body treatment product
IL205478A0 (en) Pharmaceutical compo sition for use in the treatment of breast engorgement
GB201017354D0 (en) Treatment of cancer